Compare IAC/Interactivecorp (PPLI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Sana Biotechnology Inc — how do they compare? IAC/Interactivecorp trades at $43.41 (market cap $3.28B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: IAC/Interactivecorp is far larger — about 3.7× Sana Biotechnology Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| PPLI | SANA | |
|---|---|---|
Market Cap | $3.28B | $879.40M |
Sector | Media | Health |
52-Week High | $47.62 | $5.92 |
52-Week Low | $31.52 | $2.68 |
Enterprise Value | $3.58B | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $44.09, down 0.99% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows mixed fundamentals with declining revenue from $5.2B in 2022 to $2.4B in 2025 and negative EPS misses in recent quarters, though net income margin improved to -4.35% from -14.19% in 2024. Recent news highlights potential MGM acquisition talks and upcoming Q2 2026 earnings call on August 4th.
The stock presents a value opportunity with P/B of 0.73 and strong analyst support (63.6% buy rating, $55.40 consensus target), but faces execution risks from consecutive earnings misses and negative cash flow trends. Key catalysts include MGM deal progress and Q2 results, while competitive pressures and volatile profitability remain concerns.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
